The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.

Abstract

BACKGROUND:

We have shown that thyroid-stimulating hormone (TSH) has a direct inhibitory effect on osteoclastic bone resorption and that TSH receptor (TSHR) null mice display osteoporosis. To determine the stage of osteoclast development at which TSH may exert its effect, we examined the influence of TSH and agonist TSHR antibodies (TSHR-Ab) on osteoclast differentiation from murine embryonic stem (ES) cells to gain insight into bone remodeling in hyperthyroid Graves' disease.

METHODS:

Osteoclast differentiation was initiated in murine ES cell cultures through exposure to macrophage colony stimulation factor, receptor activator of nuclear factor кB ligand, vitamin D, and dexamethasone.

RESULTS:

Tartrate resistant acid phosphatase (TRAP)-positive osteoclasts formed in ~12 days. This coincided with the expected downregulation of known markers of self renewal and pluripotency (including Oct4, Sox2, and REX1). Both TSH and TSHR-Abs inhibited osteoclastogenesis as evidenced by decreased development of TRAP-positive cells (~40%-50% reduction, p = 0.0047), and by decreased expression, in a concentration-dependent manner, of osteoclast differentiation markers (including the calcitonin receptor, TRAP, cathepsin K, matrix metallo-proteinase-9, and carbonic anhydrase II). Similar data were obtained using serum immunoglobulin-Gs (IgGs) from patients with hyperthyroid Graves' disease and known TSHR-Abs. TSHR stimulators inhibited tumor necrosis factor-alpha mRNA and protein expression, but increased the expression of osteoprotegerin (OPG), an antiosteoclastogenic human soluble receptor activator of nuclear factor кB ligand receptor. Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG.

CONCLUSION:

These data establish ES-derived osteoclastogenesis as an effective model system to study the regulation of osteoclast differentiation in early development. The results support the observations that TSH has a bone protective action by negatively regulating osteoclastogenesis. Further, our results implicate TSHR-Abs in offering skeletal protection in hyperthyroid Graves' disease, even in the face of high thyroid hormone and low TSH levels.

• Authors: Risheng Ma, Syed Morshed, Rauf Latif, Mone Zaidi, Terry F Davies
• Journal: Thyroid : official journal of the American Thyroid Association (Thyroid) Vol. 21 Issue 8 Pg. 897-906 (Aug 2011) ISSN: 1557-9077 [Electronic] United States
• PMID: 21745106 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• RANK Ligand
• Receptors, Thyrotropin
• Tnfsf11 protein, mouse
• Tumor Necrosis Factor-alpha
• Vitamin D
• Dexamethasone
• Macrophage Colony-Stimulating Factor
• Thyrotropin

Topics

• Animals
• Cell Differentiation
• Dexamethasone (pharmacology)
• Embryonic Stem Cells (cytology)
• Homozygote
• Humans
• Macrophage Colony-Stimulating Factor (metabolism)
• Mice
• Mice, Transgenic
• Osteoclasts (cytology)
• RANK Ligand (metabolism)
• Receptors, Thyrotropin (blood, immunology)
• Thyrotropin (blood, immunology)
• Tumor Necrosis Factor-alpha (biosynthesis)
• Vitamin D (metabolism)